144
Views
0
CrossRef citations to date
0
Altmetric
Key Paper Evaluation

Efficacy, end points and eventualities: sumatriptan/naproxen versus butalbital/paracetamol/caffeine in the treatment of migraine

Pages 513-516 | Published online: 10 Jan 2014

References

  • Lipton RB, Scher AI, Kolodner K, Liberman J, Steiner TJ, Steward WF. Migraine in the United States: epidemiology and patterns of health care use. Neurology 58(6), 885–894 (2002).
  • Silberstein SD, Lipton RB. Headache epidemiology. Emphasis on migraine. Neurol. Clin. 14(2), 421–434 (1996).
  • Prevalence of headache and migraine in children and adolescents: a systematic review of population-based studies. Dev. Med. Child Neurol. 52(12), 1088–1097 (2010).
  • Tfelt-Hansen PC, Koehler PJ. One hundred years of migraine research: major clinical and scientific observations from 1910 to 2010. Headache 51(5), 752–778 (2011).
  • Cady RK, Wendt JK, Kirchner JR, Sargent JD, Rothrock JF, Skaggs H Jr. Treatment of acute migraine with subcutaneous sumatriptan. JAMA 265(21), 2831–2835 (1991).
  • Silberstein SD, McCrory DC. Butalbital in the treatment of headache: history, pharmacology, and efficacy. Headache 41(10), 953–967 (2001).
  • Goldstein J, Gawel MJ, Winner P et al. Comparison of butorphanol nasal spray and fiorinal with codeine in the treatment of migraine. Headache 38(7), 516–522 (1998).
  • Wenzel RG, Sarvis CA. Do butalbital-containing products have a role in the management of migraine? Pharmacotherapy 22(8), 1029–1035 (2002).
  • Martin VT, Loder E, Taylor K, Almas M, Hilliard B. Eletriptan treatment of migraine in patients switching from barbiturate-containing analgesics: results from a multiple-attack study. Cephalalgia 25(9), 726–734 (2005).
  • Tfelt-Hansen PC, Diener HC. Why should American headache and migraine patients still be treated with butalbital-containing medicine? Headache 52(4), 672–674 (2012).
  • Derosier F, Sheftell F, Silberstein S et al. Sumatriptan–naproxen and butalbital: a double-blind, placebo-controlled crossover study. Headache 52(4), 530–543 (2012).
  • Brandes JL, Kudrow D, Stark SR et al. Sumatriptan–naproxen for acute treatment of migraine: a randomized trial. JAMA 297(13), 1443–1454 (2007).
  • Khoury CK, Couch JR. Sumatriptan–naproxen fixed combination for acute treatment of migraine: a critical appraisal. Drug Des. Devel. Ther. 4, 9–17 (2010).
  • Fox AW, Keywood C, Sheftell FD, Spierings EL, Winner P. Comparison of therapeutic gain with therapeutic ratio for the assessment of selective 5HT(1B/1D) agonist efficacy in migraine. Headache 42(7), 680–688 (2002).
  • Meskunas CA, Tepper SJ, Rapoport AM, Sheftell FD, Bigal ME. Medications associated with probable medication-overuse headache reported in a tertiary care headache center over a 15-year period. Headache 46(5), 766–772 (2006).
  • Loder E, Biondi D. Oral phenobarbital loading: a safe and effective method of withdrawing patients with headache from butalbital compounds. Headache 43(8), 904–909 (2003).
  • Dodick D, Freitag F. Evidence-based understanding of medication-overuse headache: clinical implications. Headache 46(Suppl. 4), S202–S211 (2006).
  • Bigal ME, Borucho S, Serrano D, Lipton RB. The acute treatment of episodic and chronic migraine in the USA. Cephalalgia 29(8), 891–897 (2009).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.